Klingenstein Fields & Co. LP Buys 6,231 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Klingenstein Fields & Co. LP raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1,083.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 6,806 shares of the biopharmaceutical company’s stock after buying an additional 6,231 shares during the quarter. Klingenstein Fields & Co. LP’s holdings in Regeneron Pharmaceuticals were worth $4,848,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Rakuten Securities Inc. raised its position in shares of Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 19 shares during the period. FSA Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals during the third quarter worth approximately $26,000. Fairfield Financial Advisors LTD acquired a new position in shares of Regeneron Pharmaceuticals during the third quarter worth approximately $37,000. Private Wealth Management Group LLC raised its position in shares of Regeneron Pharmaceuticals by 260.0% during the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 39 shares during the period. Finally, Truvestments Capital LLC acquired a new position in shares of Regeneron Pharmaceuticals during the third quarter worth approximately $39,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Morgan Stanley lowered their target price on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Leerink Partnrs raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. Robert W. Baird lowered their price target on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a research report on Wednesday, February 5th. Piper Sandler lowered their price target on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a research report on Monday, January 27th. Finally, Evercore ISI lowered their price target on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $674.27 on Friday. The business’s 50-day moving average price is $710.88 and its two-hundred day moving average price is $901.80. Regeneron Pharmaceuticals, Inc. has a twelve month low of $642.00 and a twelve month high of $1,211.20. The stock has a market cap of $74.10 billion, a P/E ratio of 17.61, a PEG ratio of 2.38 and a beta of 0.08. The company has a quick ratio of 4.46, a current ratio of 4.73 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company’s revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the firm posted $11.86 EPS. As a group, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 36.67 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be issued a dividend of $0.88 per share. The ex-dividend date is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.52%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.